Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 2/20 | 0.34 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 5/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | RARG | P13631 | 5/20 | 0.32 |
| ▸ | RARB | P10826 | 4/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 5/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519345 | 0.89 | RARA (0.37) | CYP26A1CYP26B1RARARARGRARB | |
| SCHEMBL17276192 | 0.74 | PDK2 (0.33) | RARAPDK2RARGRARB | |
| SCHEMBL13613860 | 0.74 | CYP26A1 (0.37) | CYP26A1CYP26B1RARARARGRARB | |
| SCHEMBL8433747 | 0.72 | RARA (0.50) | RARAPDK2RARGRARB | |
| SCHEMBL8772764 | 0.71 | RARB (0.33) | RARAPDK2RARGRARB | |
| SCHEMBL6292935 | 0.70 | PDK2 (0.45) | CYP26A1RARAPDK2RARGRARB | |
| SCHEMBL8331635 | 0.69 | PDK2 (0.46) | RARAPDK2RARGRARB | |
| SCHEMBL8664382 | 0.69 | RARB (0.44) | RARAPDK2RARGRARB | |
| SCHEMBL13613862 | 0.69 | PDK2 (0.37) | CYP26A1CYP26B1RARAPDK2RARG | |
| SCHEMBL6293844 | 0.68 | ALDH1A1 (0.35) | CYP26A1CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CYP26A1 15/4885CYP26B1 10/4885ACLY 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.